Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST


Get your full text copy in PDF

Delirium due to Buprenorphine therapy

Alexander Kaptsan, Darwin Telias

CaseRepClinPractRev 2003; 4(3):182-185

ID: 450617

Background: Buprenorphine, a mixed agonist-antagonist opioid, is a potent analgesic that appears to be effective for the maintenance treatment of opiate abuse. We did not find published reports of buprenorphine-induced delirium in opioid users and now describe a patient who developed delirium probably due to buprenorphine treatment.
Case report: The following report describes a case in which a physically healthy patient suffering from opioid abuse developed delirium under buprenorphine therapy. The patient was confused, had visual and verbal hallucinations, delusions of reference, influence and persecution, which were successfully treated by termination of buprenorphine and treatment with haloperidol.
Conclusions: The intention of this report is to draw new attention to the adverse event, which may represent a dangerous side effect of treatment with a relatively novel medication. Some speculations about possible mechanisms and clinical implication are discussed. Further systematic study would be required, if a significant number of cases.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree